Non Hodgkin Lymphoma (NHL) Market Report
Non-Hodgkin Lymphoma (NHL) Market, By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, Others), Application (Hospital, Clinic), and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Non-Hodgkin Lymphoma (NHL) market. The historic years considered for the study are 2016-2019, the base year is 2020, and the forecast period is 2021-2026.
Non-Hodgkin Lymphoma (NHL) Market, By Drug Class (Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, Others), Application (Hospital, Clinic), and Region - COVID-19 Impact Anal...
Impact of COVID-19 on Non Hodgkin Lymphoma (NHL) Market
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Non-Hodgkin Lymphoma (NHL) market is projected to grow from USD 8.1 billion in 2020 to USD 12.4 billion by 2026 at a CAGR of around 7.4% during the forecast period.
Non-Hodgkin lymphoma also referred to as non-Hodgkin's lymphoma, NHL, or lymphoma is a type of cancer that starts in white blood cells called lymphocytes, a part of the body’s immune system. The various types of drugs used to treat Non-Hodgkin lymphoma include monoclonal antibodies, antibody-drug conjugates, btk/bcl-2 kinase inhibitors, pi3 kinase inhibitors, protease inhibitors, and others.
Key players operating in the Non-Hodgkin Lymphoma (NHL) market are-
The growth of the non-Hodgkin lymphoma (NHL) market is primarily driven by increasing incidences of lymphoma cancer disease across geographies. Changing lifestyles and unhealthy diets are some of the factors resulting in cancer disease, which is likely to drive the market growth at a significant rate during the review period. In addition to this, surging demand for new cancer treatment drugs is likely to create lucrative opportunities for the players operating in the global market in the coming years.
By type, the non-Hodgkin lymphoma (NHL) market has been bifurcated into hospitals and clinics. Under these, the hospital segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment growth can be attributed to the presence of established infrastructure and skilled healthcare staff.
By region, the market in North America accounted for the largest market share in 2020 and is projected to grow at a significant CAGR during the assessment period. The segment growth is primarily attributed to the rising number of people suffering from lymphoma cancer coupled with the presence of key market players such as Bristol Myers Squibb (US) and Celgene Corporation (US). The market growth in the Asia-Pacific region is expected to be driven by the increasing prevalence of cancer disease.
The outbreak of the COVID-19 virus has affected the growth of the healthcare industry significantly. Stringent lockdown measures and restricted movement of people affected the number of visits to the hospital for cancer treatment due to high focus on treating covid-19 patients and fear of infection.
Here is the list of the group of customers that the non-hodgkin lymphoma market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at email@example.com.
The non-Hodgkin lymphoma market is expected to witness an impressive growth of 7.4% CAGR in the coming years.
F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (US), The Merck Group (Germany), Bristol Myers Squibb (US), Celgene Corporation (US), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Bayer AG (Germany), AstraZeneca plc (UK) and The Takeda Pharmaceutical Company Limited (Japan) are among the key players in the non-Hodgkin lymphoma market.
The non-Hodgkin lymphoma market size is expected to reach USD 12.4 billion in the foreseeable future.
The hospital segment is expected to register significant growth in the non-Hodgkin lymphoma market in the coming years.
North America accounted for the largest share in the non-Hodgkin lymphoma market in the next five years.
Non-Hodgkin lymphoma (NHL) distributors, Non-Hodgkin lymphoma (NHL) suppliers, Non-Hodgkin lymphoma (NHL) manufacturers, Logistics organizations, Government bodies are the target audience in the non-Hodgkin lymphoma market.